
Drug Affinity Responsive Target Stability Assay Kit (DARTS Assay Kit)
$800.00 - $2,400.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: DARTS-100 (for 100T)
Cat. No.: DARTS-500 (for 500T)
Description
Drug Affinity Responsive Target Stability Assay Kit (DARTS Assay Kit)—also known as Drug Target Identification Kit, Label-Free Drug–Protein Interaction Kit, or Target Stability Assay Kit—is based on drug affinity–responsive target stabilization technology. Without any chemical labeling, this kit enables simple and rapid assessment of how candidate drugs affect the stability of known or unknown target proteins.
On one hand, it allows screening of candidate drugs that enhance the stability of known target proteins through Western blotting, ELISA, or enzymatic assays. On the other hand, it can be used with LC-MS/MS to identify unknown target proteins that become more stable upon drug binding.
DARTS (Drug Affinity Responsive Target Stability) is a method used to identify drug targets by detecting changes in protein stability induced by drug–protein interactions. It offers a relatively fast and direct approach to discovering small-molecule protein targets, and can also validate protein–ligand interactions predicted by other methods while assessing their binding affinity [1]. Since its introduction in 2009, DARTS has been widely applied in the research of small-molecule drug targets.
Current approaches to target identification fall into two categories:
Affinity-based methods, such as affinity chromatography, activity-based probes, and protein microarrays, detect direct interactions between drugs and their targets. However, these techniques often require chemical modification of drugs or proteins, which may be limited by a lack of conjugation sites or risk affecting drug–target binding.
Phenotype-based methods, such as genomics and proteomics, infer targets through cellular or organismal responses to drugs. These methods rely on biological effects triggered by drug treatment.
Compared to these approaches, DARTS uses unmodified drug molecules to interact directly with proteins, without relying on chemical synthesis or biological responses. It is applicable to any small-molecule drug, regardless of mechanism, and can be used with any organism, cell type, or tissue—without being limited by knockout libraries.
Protein degradation in cells primarily occurs through the ubiquitin–proteasome system (UPS), autophagy–lysosome pathway, or direct lysosomal degradation. Protein stability in vivo is often difficult to predict, but some drugs or ligands—particularly small molecules—bind with high specificity to target proteins, which can either increase or decrease their susceptibility to proteases. In some cases, small molecules stabilize proteins by inducing specific conformational changes or masking protease recognition sites, thus enhancing protein stability.
This kit is primarily based on DARTS (Drug Affinity Responsive Target Stability) technology. After incubating small-molecule drugs with protein samples for a set period, proteases are added to initiate digestion. Drug binding alters the target protein's susceptibility to proteolytic degradation. The relative abundance of the target protein can then be assessed by SDS-PAGE, Coomassie Brilliant Blue staining, or Western blotting. Additionally, unknown drug targets can be identified using techniques such as two-dimensional electrophoresis (2D-PAGE), LC-MS, or affinity chromatography.
One of the key steps in the DARTS assay system is the addition of an appropriate concentration of protease. The protease included in this kit specifically cleaves peptide bonds at the carboxyl side of aspartic acid and glutamic acid residues in both folded and unfolded proteins and polypeptide chains. Verified through testing, this protease exhibits strong activity under neutral pH conditions, ensuring high efficiency and accuracy in the digestion process within the DARTS system.
Components
- Lysis Buffer
- Protease
- Protease Inhibitor Cocktail (100X)
- Loading Buffer (6X)
Features
- Simple & Highly Reproducible: This kit offers a simple and highly reproducible workflow, allowing small-molecule drugs to be tested in their native form without any chemical labeling. The ability to use unmodified compounds significantly streamlines the experimental process, reduces time and cost, and avoids potential loss of drug activity or altered target specificity caused by chemical derivatization. Because labeling is unnecessary, results more accurately reflect the drug’s effect under physiological conditions, ensuring both reliability and reproducibility.
- Broad Applicability: The kit is compatible with a wide range of cell types, including mammalian cells, tissue extracts, and other complex protein samples—demonstrating excellent experimental versatility.
- High Sensitivity: With no washing steps required in the workflow, the kit enables highly sensitive detection of low-abundance or weakly binding small-molecule targets. Even in complex protein backgrounds, it reliably identifies target proteins, supporting discovery and validation of drug–target interactions and accelerating drug development.
- Excellent Compatibility: Protein samples prepared using this kit are compatible with a variety of downstream analytical techniques, including SDS-PAGE, Coomassie Brilliant Blue staining, Western blotting, enzyme activity assays, two-dimensional electrophoresis (2D-PAGE), and LC-MS. This analytical flexibility allows researchers to select the most appropriate detection method for their needs, enabling comprehensive and in-depth data acquisition, and enhancing both reliability and diversity of experimental outcomes.
- Convenient to Use: Unlike other drug target identification methods that require complex instrumentation and costly reagents, this kit provides a user-friendly and validated solution for streamlined research.
Storage
Store at -20ºC. Valid for one year.
Precautions
- Please prepare test compounds as needed. We recommend using our Approved Drug Library (2,818 compounds, 10 mM × 10 μl).
- Please prepare primary antibodies against target proteins as needed. Our antibody library is recommended for selecting suitable options.
- Validated results show that the prepared Protease solution maintains performance after up to three freeze–thaw cycles. Nevertheless, repeated freeze–thawing should be avoided when possible.
- Protease Inhibitor Cocktail (100×) and Loading Buffer (6×) are hazardous to human health. Handle with care and take appropriate safety precautions to avoid direct contact or inhalation.
- This product is intended for research use only by trained professionals. It must not be used for clinical diagnosis or treatment, food or pharmaceutical applications, or stored in residential environments.
- For your safety and health, always wear a lab coat and disposable gloves during handling.
Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory

